This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Varenicline Treatment for Smokers With Schizophrenia: A Case Series

A. Eden Evins, MD, MPH, and Donald C. Goff, MD

Published: June 30, 2008

Article Abstract

Letter to the Editor

Sir: Schizophrenia is associated with increased prevalenceof smoking, heavy smoking, and smoking-related morbidity andmortality. Standard nicotine dependence treatments have beenassociated with modest efficacy in patients with schizophreniaand high rates of relapse to smoking upon their discontinuation.Varenicline was approved for nicotine dependencetreatment in 2006.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 69

Quick Links: Addiction , Smoking

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...